AbCellera Biologics (ABCL) Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AbCellera Biologics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ABCL shares.
View ABCL analyst ratings or view top-rated stocks.

8 Wall Street analysts have issued twelve-month target prices for AbCellera Biologics' shares. Their ABCL share price forecasts range from $12.00 to $34.00. On average, they predict the company's stock price to reach $23.13 in the next year. This suggests a possible upside of 362.5% from the stock's current price.
View analysts price targets for ABCL or view top-rated stocks among Wall Street analysts.

AbCellera Biologics' stock was trading at $10.13 at the beginning of the year. Since then, ABCL shares have decreased by 50.6% and is now trading at $5.00.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our ABCL earnings forecast.

AbCellera Biologics Inc. (NASDAQ:ABCL) released its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.13) by $0.02. The business earned $10.10 million during the quarter, compared to the consensus estimate of $12.38 million. AbCellera Biologics had a negative net margin of 50.91% and a negative trailing twelve-month return on equity of 6.05%. The company's revenue for the quarter was down 78.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.02) earnings per share.

ETFs with the largest weight of AbCellera Biologics (NASDAQ:ABCL) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM).TrueShares Technology, AI & Deep Learning ETF (LRNZ).

(ABCL) raised $356 million in an initial public offering on Friday, December 11th 2020. The company issued 23,000,000 shares at a price of $14.00-$17.00 per share. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets acted as the underwriters for the IPO.

AbCellera Biologics trades on the NASDAQ under the ticker symbol "ABCL."

AbCellera Biologics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (9.13%), Capital World Investors (2.91%), Credit Suisse AG (1.58%), ArrowMark Colorado Holdings LLC (1.42%), BlackRock Inc. (1.19%) and Lazard Asset Management LLC (1.13%). Insiders that own company stock include Andrew Booth, Andrew Lo, Carl L G Hansen, Holdings Ltd Thermopylae, John Hamer, John S Montalbano, Michael R Hayden and Veronique Lecault.
View institutional ownership trends.

Shares of ABCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ABCL stock can currently be purchased for approximately $5.00.

AbCellera Biologics (NASDAQ:ABCL) has a market capitalization of $1.45 billion and generates $485.42 million in revenue each year. The company earns $158.52 million in net income (profit) each year or ($0.27) on an earnings per share basis.

The company employs 590 workers across the globe.

The official website for the company is www.abcellera.com. The company can be reached via phone at 604-559-9005 or via email at ir@abcellera.com.